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Background: Few comparative data exist on in-hospital bleeding events with the concurrent use of clopidogrel, prasugrel and ticagrelor in real-life 
patients with ACS undergoing percutaneous coronary intervention (PCI).
methods: We performed detailed recording of bleeding events (Bleeding Academic Research Consortium -BARC classification) in the context of a 
prospective multi-centre, observational study of antiplatelet treatment patterns in ACS patients subjected to PCI in Greece.
results: From January to August 2012, out of 875 patients registered, 333 subjected to in-hospital P2Y12-inhibitor switching and 2 died without 
receiving any P2Y12-inhibitor, leaving 540 patients to be included in analysis (81.9% men, 23.1% diabetics, with a mean age of 63.1±12.6 years). In 
total, 23(4.3%), 13(2.4%) and 12(2.2%) patients presented an in-hospital BARC1, BARC2 and BARC3 bleeding event respectively. No fatal bleeding 
event occurred. In multivariate (logistic regression) analysis, age≥75 years, prior bleeding and ticagrelor or prasugrel use emerged as independent 
risk factors for any BARC bleeding event (Figure)
conclusions: In a real-world PCI-treated ACS population, prasugrel and ticagrelor use is associated with an increased risk of low to moderate 
severity bleeding events.
 
